| Principal Investigator |
Funding Agency |
Title |
| Boriosi, Juan |
Hoffmann-La Roche, Inc |
An Open Label Prospective, Pharmacokinetic/Pharmacodynaic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Infants Less Than One Year of Age with Infeluenza Infection, Protocol # NP25138C |
| Boriosi, Juan |
Hoffmann-La Roche, Inc |
An open label prospective, pharmacokinetic/pharmacodynaic and safety evaluation of intravenous oseltamivir (Tamiflu) in the treatment of children 1 to 12 years of age with influenza infection, Protocol # NP25139C |
| Boriosi, Juan |
Purdue Pharma |
A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety and Efficacy of Intravenous Dosing on Buprenorphine in Pediatric Patients Aged from Birth to 6 Years of Age Who Require Opiodi Analgesia for Aactue Moderate to Severe Pain |
| Boriosi, Juan |
University of California - San Francisco |
Targeted Genomic Analysis of Coagulation Pathyways in Acute Lung Injury |
| Cengiz, Pelin |
DHHS, PHS, National Institutes of Health |
Role of Na+/H+ exchanger isoform 1 (NHE-1) in hippocampal astrocytes after neonatal hypoxia and ischemia (ICTR KL2) |
| Eldridge, Marlowe |
UWF - University of Wisconsin Foundation |
SMPH Emergency Support |
| Eldridge, Marlowe |
DHHS, PHS, National Institutes of Health |
Comprehensive Characterization of Intrapulmonary Arteriovenous Pathways |
| Eldridge, Marlowe |
DOD, Navy |
Salary Support, Aleksey Sobakin |
| Ferrazzano, Peter |
DHHS, PHS, National Institutes of Health |
MRI Biomarkers of Pediatric Brain Injury and Neuroprotection (ICTR KL2) |
| Wilhelm, Michael |
DHHS, PHS, National Institutes of Health |
Regulation of Dendritic APP translation by the JNK Pathway in Fragile X Syndrome (ICTR KL2) |
| Wilhelm, Michael |
Fraxa Research Foundation |
The Role of JNK in FMRP Regulated Translation in Fragile X Syndrome - T. Schmit Postdoctoral Fellowship |
